ALD2 Antibody

What is the difference between ALD2 and ALDH2 antibodies?

ALD2 and ALDH2 antibodies target different aldehyde dehydrogenase enzymes depending on the species. ALDH2 antibodies typically target mitochondrial aldehyde dehydrogenase in mammals, which plays a crucial role in the clearance of cellular formaldehyde—a cytotoxic and carcinogenic metabolite that induces DNA damage . In contrast, ALD2 antibodies commonly refer to those targeting aldehyde dehydrogenase in Saccharomyces cerevisiae (yeast) . These target proteins have different structures and cellular functions despite their related enzymatic activities. When selecting an antibody, researchers must carefully consider the target species and confirm the proper nomenclature to avoid experimental confusion.

What species reactivity can I expect from different ALD2/ALDH2 antibodies?

ALDH2 antibodies exhibit varying cross-reactivity patterns based on their development. Many commercially available ALDH2 antibodies demonstrate reactivity with human, mouse, and rat samples due to the high sequence conservation of ALDH2 across mammalian species . For instance, Mouse Anti-Human/Mouse/Rat ALDH2 Monoclonal Antibody (MAB10168) has confirmed reactivity against human, mouse, and rat liver tissue samples in Western blot applications . Rabbit polyclonal antibodies like DF6358 show similar reactivity patterns and additionally predict possible cross-reactivity with pig, bovine, horse, sheep, rabbit, dog, and Xenopus samples based on sequence alignment analysis . For researchers working with yeast models, ALD2-specific antibodies are available with confirmed reactivity against Saccharomyces cerevisiae .

What are the common applications for ALD2/ALDH2 antibodies?

ALD2/ALDH2 antibodies support multiple experimental approaches in molecular and cellular biology:

Western blot remains the most versatile application across all antibody options, while immunohistochemistry (IHC) is supported by most mammalian ALDH2 antibodies . For yeast research, ALD2 antibodies additionally support immunoprecipitation (IP) and ELISA applications .

What are the optimal sample preparation methods for ALD2/ALDH2 Western blot experiments?

Successful Western blot detection of ALDH2 requires careful consideration of sample preparation protocols. For mammalian ALDH2 detection, tissue lysates (particularly liver) typically provide robust signal when prepared under reducing conditions using standard lysis buffers . Experimental data confirms that human, mouse, and rat liver lysates consistently yield clear bands at approximately 56 kDa when probed with anti-ALDH2 antibodies . For cell line samples, researchers should verify ALDH2 expression levels, as demonstrated by the differential detection between SK-BR-3 cells (positive) and MCF-7 cells (negative) using MAB10168 .

For ALD2 detection in yeast samples, standard yeast lysis protocols involving mechanical disruption (glass beads or sonication) in appropriate buffer systems yield reliable results. Western blot dilutions should be optimized within the range of 1:500-1:2,000 for optimal signal-to-noise ratio .

How should I optimize antibody dilutions for different applications?

Optimal antibody dilutions vary by application and specific antibody. Based on compiled technical data:

For Western blot:

• MAB10168: 2 μg/mL provides optimal detection in human, mouse, and rat liver tissue lysates

• DF6358: Requires end-user optimization but typically works in standard Western blot dilution ranges

• ALD2 antibody (200-4144-0100): 1:500-1:2,000 dilution range is recommended

For immunohistochemistry:

• MAB10168: 0.5-8 μg/mL, with 0.5 μg/mL effective for paraffin-embedded tissue sections following heat-induced epitope retrieval

For immunofluorescence:

• MAB10168: 8 μg/mL for cell line staining with appropriate fluorescent secondary antibodies

For immunoprecipitation:

• ALD2 antibody (200-4144-0100): 1:100 dilution is recommended

For ELISA:

• ALD2 antibody (200-4144-0100): 1:5,000-1:20,000 dilution range provides optimal results

What controls should I include when using ALD2/ALDH2 antibodies?

Rigorous experimental design requires appropriate controls to validate antibody specificity and ensure reliable interpretation of results. When working with ALDH2 antibodies:

• Positive control samples: Include human, mouse, or rat liver tissue, which consistently expresses high levels of ALDH2

• Cell line controls: Consider using SK-BR-3 cells (ALDH2-positive) and MCF-7 cells (ALDH2-negative) as demonstrated in immunocytochemistry applications

• Loading controls: Include appropriate housekeeping protein detection to normalize protein loading

• Secondary antibody-only controls: Verify the absence of non-specific binding by secondary antibodies

• Cross-reactivity controls: For researchers working across species, include samples from non-target species to confirm specificity claims

For yeast ALD2 experiments, wild-type yeast strains serve as positive controls, while ALD2 deletion mutants provide excellent negative controls to confirm antibody specificity .

How can I validate the specificity of ALD2/ALDH2 antibodies?

Antibody specificity validation is critical for ensuring experimental reproducibility and accurate data interpretation. For ALDH2 antibodies, multiple validation approaches should be employed:

• Western blot validation: Verify that the antibody detects a single band at the expected molecular weight (approximately 56 kDa for ALDH2) . Both MAB10168 and DF6358 have been validated to detect appropriate bands in human, mouse, and rat liver tissue lysates .

• Orthogonal detection: Compare results using different antibody clones targeting distinct epitopes of the same protein. MAB10168 (monoclonal) and DF6358 (polyclonal) can be used complementarily to confirm ALDH2 detection .

• Simple Western validation: Automated capillary-based immunoassays provide an alternative detection method to confirm antibody specificity. MAB10168 has been validated using this approach, detecting ALDH2 at approximately 55 kDa in human, mouse, and rat liver tissue lysates .

• Immunohistochemical localization: Confirm appropriate subcellular localization consistent with mitochondrial distribution for ALDH2. MAB10168 has been validated to show cytoplasmic localization in human kidney tissue sections .

• Genetic approaches: When possible, employ knockout/knockdown samples or overexpression systems to verify antibody specificity against varying levels of target protein.

What are common issues in Western blot detection with these antibodies?

Researchers frequently encounter several technical challenges when using ALD2/ALDH2 antibodies in Western blot applications:

• Suboptimal signal strength: ALDH2 detection in non-liver tissues may require higher antibody concentrations due to lower expression levels. Increasing from 2 μg/mL to 5-10 μg/mL of primary antibody may improve detection .

• Background noise: Non-specific binding can be reduced by optimizing blocking conditions and implementing more stringent washing protocols. For MAB10168, using Immunoblot Buffer Group 1 under reducing conditions provides optimal results .

• Multiple bands: While ALDH2 should appear as a single band at ~56 kDa, post-translational modifications or proteolytic degradation may produce additional bands. Confirming with multiple antibody clones helps distinguish specific from non-specific signals.

• Cross-reactivity with other ALDH family members: Due to sequence similarity among aldehyde dehydrogenase family proteins, antibodies may exhibit cross-reactivity. Careful antibody selection focusing on unique epitopes reduces this risk.

• Sample preparation issues: Proper sample preparation is critical; ALDH2 detection requires reducing conditions for optimal epitope exposure .

How do I optimize immunostaining protocols for ALDH2 detection?

Successful immunostaining of ALDH2 in tissue sections or cell preparations requires protocol optimization:

For paraffin-embedded tissue sections:

• Antigen retrieval: Heat-induced epitope retrieval using basic pH buffers (like Antigen Retrieval Reagent-Basic) enhances ALDH2 detection .

• Antibody concentration: Start with 0.5 μg/mL of MAB10168 for a 1-hour room temperature incubation .

• Detection systems: HRP-polymer detection systems provide excellent sensitivity for ALDH2 visualization in tissue sections, with DAB as the chromogen and hematoxylin counterstaining .

For immunofluorescence on cultured cells:

• Fixation method: Immersion fixation preserves ALDH2 antigenicity while maintaining cellular morphology.

• Antibody concentration: 8 μg/mL of MAB10168 for a 3-hour room temperature incubation produces optimal staining in SK-BR-3 cells .

• Secondary antibody selection: Fluorophore-conjugated secondary antibodies (such as NorthernLights 557-conjugated Anti-Mouse IgG) provide excellent visualization when paired with nuclear counterstains (DAPI) .

• Controls: Include both positive (SK-BR-3) and negative (MCF-7) cell lines to confirm specificity .

How can researchers use ALDH2 antibodies to investigate alcohol metabolism disorders?

ALDH2 plays a crucial role in alcohol metabolism by catalyzing the oxidation of acetaldehyde, a toxic intermediate product of ethanol metabolism. Research applications examining ALDH2 in alcohol metabolism disorders can leverage various antibody-dependent techniques:

• Tissue expression profiling: Using ALDH2 antibodies for immunohistochemistry allows researchers to examine ALDH2 expression patterns in liver biopsies from patients with alcoholic liver disease compared to controls .

• Genetic variant analysis: Different ALDH2 genetic variants (particularly the ALDH2*2 allele common in East Asian populations) result in altered protein expression and function. Western blot analysis using ALDH2 antibodies can quantify protein levels across genotypes .

• Subcellular localization studies: Immunofluorescence approaches using ALDH2 antibodies can track potential changes in mitochondrial localization of ALDH2 under various metabolic stresses .

• Protein-protein interaction networks: Immunoprecipitation followed by mass spectrometry can identify ALDH2 binding partners that may influence alcohol metabolism efficiency.

• Post-translational modification assessment: Western blot analysis of ALDH2 may reveal shifts in molecular weight or multiple banding patterns indicative of phosphorylation, acetylation, or other modifications affecting enzyme activity.

What is the significance of ALDH2 in cancer research and how can these antibodies contribute?

ALDH2 has emerging significance in cancer biology beyond its role in alcohol metabolism. ALDH2 antibodies support several cancer research applications:

• Cancer stem cell identification: ALDH activity, including ALDH2, serves as a marker for cancer stem cells in various tumor types. Immunostaining with ALDH2 antibodies can help characterize these populations.

• Chemotherapy resistance mechanisms: ALDH2 contributes to detoxification of certain chemotherapeutic agents. Western blot analysis of ALDH2 levels before and after treatment can provide insights into resistance mechanisms .

• Differential expression analysis: The differential detection of ALDH2 between cancer cell lines (e.g., positive in SK-BR-3 but negative in MCF-7 breast cancer cells) suggests cell-type specific roles that warrant investigation .

• Formaldehyde detoxification: ALDH2's role in clearing cellular formaldehyde (a cytotoxic and carcinogenic metabolite that induces DNA damage) makes it relevant to cancer development and progression .

• Biomarker development: Tissue microarray analysis using ALDH2 antibodies may help establish ALDH2 as a prognostic or predictive biomarker for specific cancer types.

What are the considerations when investigating ALDH2 in neurodegenerative disorders?

Emerging research implicates ALDH2 in neurodegenerative conditions through its detoxification activities. When investigating these connections:

• Brain region specificity: ALDH2 antibodies can be used for immunohistochemical mapping of expression across different brain regions in normal and disease states .

• Neuronal vs. glial expression: Double immunofluorescence staining using ALDH2 antibodies alongside neuronal or glial markers can determine the cellular distribution of ALDH2 in neural tissues.

• Oxidative stress response: Western blot analysis of ALDH2 levels in response to oxidative stressors may reveal regulatory mechanisms relevant to neurodegeneration .

• Animal models: ALDH2 antibodies with cross-reactivity to mouse and rat samples facilitate translational research using rodent models of neurodegeneration .

• Post-mortem tissue analysis: When working with human post-mortem brain tissue, optimized immunohistochemistry protocols using ALDH2 antibodies can reveal disease-associated changes in expression or localization.

How can researchers optimize multiplexed detection protocols involving ALDH2?

Multiplexed detection allows simultaneous visualization of ALDH2 alongside other proteins of interest:

• Antibody host species selection: When designing multiplexed immunostaining, select primary antibodies from different host species (mouse anti-ALDH2 MAB10168 vs. rabbit anti-ALDH2 DF6358 ) to enable simultaneous detection with species-specific secondary antibodies.

• Fluorophore combination strategies: For immunofluorescence multiplexing, pair ALDH2 detection with spectrally distinct fluorophores. MAB10168 has been successfully used with NorthernLights 557-conjugated Anti-Mouse IgG (red) alongside DAPI nuclear counterstain (blue) .

• Sequential detection protocols: For challenging multiplexed applications, sequential staining protocols with appropriate blocking steps between antibody pairs minimize cross-reactivity issues.

• Validation controls: Always include single-stained samples alongside multiplexed samples to confirm antibody specificity and absence of bleed-through between detection channels.

• Compatible buffer systems: Ensure all antibodies in the multiplexed panel perform optimally in the selected buffer system or modify protocols to accommodate differential requirements.